Darya S. Mamchich
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Darya S. Mamchich has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Alina V. Solovyeva
RUDN University
8 shared publications - M. A. Spitsyna
Peoples’ Friendship University of Russia named after Patrice Lumumba
7 shared publications - D. B. Rudenko
RUDN University
4 shared publications - Svetlana Aleksandrovna Rachina
I.M. Sechenov First Moscow State Medical University (Sechenov University)
4 shared publications - Ekaterina Yu. Aleynikova
Peoples’ Friendship University of Russia named after Patrice Lumumba
3 shared publications - Daria Strelkova
Department of Hospital Therapy #2, I.M. Sechenov First Moscow State Medical University, Moscow, Russia, mma.ru
2 shared publications
Latest Publications
- Open Access
- 31 May 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- Vol. 20 (5) , 120-127
Prediction of preeclampsia in pregnant women with comorbid conditions
Introduction. Preeclampsia is a serious complication of pregnancy and one of the main causes of maternal and perinatal morbidity and mortality. It is important to identify women at high risk of developing preeclampsia in the first trimester of pregnancy in order to provide timely therapeutic intervention. At the moment, there is no significant progress in predicting and preventing this complication of pregnancy. Aim. To predict the occurrence of preeclampsia in pregnant women with comorbidity. Materials and methods. A retrospective analysis of the exchange cards and birth histories of 158 residents of the Stavropol Territory was conducted. The study was conducted on the basis of the Stavropol Regional Clinical Perinatal Center in Stavropol, Stavropol Territory. Pregnant women (n = 158) were divided into three groups: the first group (n = 58) – pregnant women with overweight or obesity; group 2 (n = 70) – pregnant women with iron deficiency anemia and overweight or obesity; group 3 (n = 60) – pregnant women with iron deficiency anemia and normal body weight. Results. Pregnant women with obesity and anemia had a higher risk of vulvovaginal candidiasis (χ 2 = 8.015, p = 0.019), premature birth (χ 2 = 7.431, p = 0.025) and preeclampsia (χ 2 = 6.456, p = 0.040). For obese pregnant women, the most significant factors in the prognosis of preeclampsia were: the first pregnancy, the APTT level in the third trimester. For pregnant women with IDA, factors predicting the development of preeclampsia: first pregnancy, smoking, hemoglobin levels in the first trimester. For pregnant women with obesity and IDA, the prognostic criteria for preeclampsia were: the first pregnancy, and the indicator of thrombin time in the third trimester. Conclusions. The identification of prognostic criteria for individual risk factors for preeclampsia makes it possible to more accurately assess the likelihood of preeclampsia and timely resolve the issue of prevention and initiation of therapy and contribute to the elimination of modifiable risk factors for preeclampsia, such as obesity and anemia.
- 31 May 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- Vol. 20 (5) , 120-127
Open AccessPrediction of preeclampsia in pregnant women with comorbid conditions
Introduction. Preeclampsia is a serious complication of pregnancy and one of the main causes of maternal and perinatal morbidity and mortality. It is important to identify women at high risk of developing preeclampsia in the first trimester of pregnancy in order to provide timely therapeutic intervention. At the moment, there is no significant progress in predicting and preventing this complication of pregnancy. Aim. To predict the occurrence of preeclampsia in pregnant women with comorbidity. Materials and methods. A retrospective analysis of the exchange cards and birth histories of 158 residents of the Stavropol Territory was conducted. The study was conducted on the basis of the Stavropol Regional Clinical Perinatal Center in Stavropol, Stavropol Territory. Pregnant women (n = 158) were divided into three groups: the first group (n = 58) – pregnant women with overweight or obesity; group 2 (n = 70) – pregnant women with iron deficiency anemia and overweight or obesity; group 3 (n = 60) – pregnant women with iron deficiency anemia and normal body weight. Results. Pregnant women with obesity and anemia had a higher risk of vulvovaginal candidiasis (χ 2 = 8.015, p = 0.019), premature birth (χ 2 = 7.431, p = 0.025) and preeclampsia (χ 2 = 6.456, p = 0.040). For obese pregnant women, the most significant factors in the prognosis of preeclampsia were: the first pregnancy, the APTT level in the third trimester. For pregnant women with IDA, factors predicting the development of preeclampsia: first pregnancy, smoking, hemoglobin levels in the first trimester. For pregnant women with obesity and IDA, the prognostic criteria for preeclampsia were: the first pregnancy, and the indicator of thrombin time in the third trimester. Conclusions. The identification of prognostic criteria for individual risk factors for preeclampsia makes it possible to more accurately assess the likelihood of preeclampsia and timely resolve the issue of prevention and initiation of therapy and contribute to the elimination of modifiable risk factors for preeclampsia, such as obesity and anemia.
- 11 May 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 4,p. 132-140
Diagnostic significance of placental growth factor in women with unspecified preeclampsia
Introduction . Up to 10% of pregnant women suffer from hypertensive disorders, but preeclampsia (PE) occupies a special place, complicating approximately 2–8% of gestations worldwide. Aim. The pathogenesis of PE is not fully understood, but there is no doubt that it is closely related to angiogenic imbalance. Materials and methods. The study included 72 patients admitted to an obstetric hospital with suspected PE. Depending on the value of PLGF, the participants were divided into 3 groups: patients with a high risk of placental dysfunction (n = 37) (100 pg/ml). Results. In patients with a high risk of placental dysfunction, severe PE was statistically significantly more common, as was the shortest interval before premature delivery, as well as adverse maternal and neonatal outcomes. Based on the level of PLGF and proteinuria, a prognostic model was developed to determine the likelihood of developing severe PE, with a specificity and sensitivity of 94.0% and 81.8%, respectively. Conclusions. The introduction of PLGF analysis into clinical practice can help predict severe PE, simplify risk stratification, and implement personalized treatment strategies and dynamic monitoring, which can improve maternal and perinatal outcomes.
- 11 May 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 4,p. 132-140
Diagnostic significance of placental growth factor in women with unspecified preeclampsia
Introduction . Up to 10% of pregnant women suffer from hypertensive disorders, but preeclampsia (PE) occupies a special place, complicating approximately 2–8% of gestations worldwide. Aim. The pathogenesis of PE is not fully understood, but there is no doubt that it is closely related to angiogenic imbalance. Materials and methods. The study included 72 patients admitted to an obstetric hospital with suspected PE. Depending on the value of PLGF, the participants were divided into 3 groups: patients with a high risk of placental dysfunction (n = 37) (100 pg/ml). Results. In patients with a high risk of placental dysfunction, severe PE was statistically significantly more common, as was the shortest interval before premature delivery, as well as adverse maternal and neonatal outcomes. Based on the level of PLGF and proteinuria, a prognostic model was developed to determine the likelihood of developing severe PE, with a specificity and sensitivity of 94.0% and 81.8%, respectively. Conclusions. The introduction of PLGF analysis into clinical practice can help predict severe PE, simplify risk stratification, and implement personalized treatment strategies and dynamic monitoring, which can improve maternal and perinatal outcomes.
- 1 January 2026
- Published by Geotar-Media Publishing Group in Obstetrics and gynecology: News, Opinions, Training
- Vol. 14 (3)
Effectiveness of programmed labor in patients with polymorbid conditions
- 1 January 2026
- Published by Geotar-Media Publishing Group in Obstetrics and gynecology: News, Opinions, Training
- Vol. 14 (3)
Effectiveness of programmed labor in patients with polymorbid conditions
- Open Access
- 20 November 2025
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 17,p. 37-42
Use of estradiol valerate in women with thin endometrium in ART cycles
Introduction . Patients with infertility often require the help of assisted reproductive technologies to solve their problem. Two thirds of failures in ART cycles are associated with insufficient endometrial receptivity. Aim . To evaluate the effectiveness of using estradiol valerate 2 mg (Progynova®) in women with thin endometrium in ART cycles. Materials and methods . The study included patients with a thin endometrium ≤ 7.0 mm according to the ultrasound examination (US) of the pelvic organs on the 10–14th day of the menstrual cycle (peak of luteinizing hormone (LH) in the blood or on the day of progesterone administration in the hormone replacement therapy cycle). Patients with a thin endometrium (n = 74) were divided into two groups: the first group (n = 43) – patients with chronic endometritis established by histological examination and immunohistochemistry (IHC); group 2 (n=31) – patients with a thin endometrium without chronic endometritis. All patients received estradiol valerate according to one of the following regimens: 4 mg estradiol valerate in a natural cycle from the moment the dominant follicle reached a diameter of 13 mm or 4 mg estradiol valerate from day 3 of the menstrual cycle. Results. Administration of estradiol valerate statistically significantly increased the endometrial thickness in women with thin endometrium (p < 0.05). The increase in endometrial thickness in patients of group 1 averaged 1.9279 mm, in patients of group 2 – 2.09 mm. The average endometrial thickness before treatment with estradiol valerate was 6.315 (4.7; 7.0) mm, after treatment – 8.311 (5.6; 11.0). 70 of 74 (94.6%) patients had an endometrial thickness of > 7 mm. Pregnancy in an IVF or PE cycle occurred in 44 patients with thin endometrium (62.5%) after treatment with estradiol valerate. Conclusions. The use of estradiol valerate in IVF and ET cycles increases the thickness of the endometrium and increases the frequency of pregnancy and live birth in patients with a thin endometrium.
- 20 November 2025
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 17,p. 37-42
Open AccessUse of estradiol valerate in women with thin endometrium in ART cycles
Introduction . Patients with infertility often require the help of assisted reproductive technologies to solve their problem. Two thirds of failures in ART cycles are associated with insufficient endometrial receptivity. Aim . To evaluate the effectiveness of using estradiol valerate 2 mg (Progynova®) in women with thin endometrium in ART cycles. Materials and methods . The study included patients with a thin endometrium ≤ 7.0 mm according to the ultrasound examination (US) of the pelvic organs on the 10–14th day of the menstrual cycle (peak of luteinizing hormone (LH) in the blood or on the day of progesterone administration in the hormone replacement therapy cycle). Patients with a thin endometrium (n = 74) were divided into two groups: the first group (n = 43) – patients with chronic endometritis established by histological examination and immunohistochemistry (IHC); group 2 (n=31) – patients with a thin endometrium without chronic endometritis. All patients received estradiol valerate according to one of the following regimens: 4 mg estradiol valerate in a natural cycle from the moment the dominant follicle reached a diameter of 13 mm or 4 mg estradiol valerate from day 3 of the menstrual cycle. Results. Administration of estradiol valerate statistically significantly increased the endometrial thickness in women with thin endometrium (p < 0.05). The increase in endometrial thickness in patients of group 1 averaged 1.9279 mm, in patients of group 2 – 2.09 mm. The average endometrial thickness before treatment with estradiol valerate was 6.315 (4.7; 7.0) mm, after treatment – 8.311 (5.6; 11.0). 70 of 74 (94.6%) patients had an endometrial thickness of > 7 mm. Pregnancy in an IVF or PE cycle occurred in 44 patients with thin endometrium (62.5%) after treatment with estradiol valerate. Conclusions. The use of estradiol valerate in IVF and ET cycles increases the thickness of the endometrium and increases the frequency of pregnancy and live birth in patients with a thin endometrium.
- Open Access
- 26 April 2025
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 4,p. 44-51
The course of pregnancy and childbirth in women with iron deficiency anemia treated with iron (II) sulfate and not treated
Introduction. Due to the plasma volume expansion prevailing over the increase in red blood cell production, as well as inadequate dietary intake with underlying physiologically increased iron requirements, pregnant women tend to suffer from iron deficiency and anaemia.Aim. To evaluate the efficacy of Tardyferon (depot iron (II) sulphate 80 mg) in pregnant women with anaemia in reducing adverse perinatal outcomes. Materials and methods. To conduct the retrospective chart review of pregnant women of Stavropol Krai, the patients were divided into 2 groups: Group 1 (n = 70) – the treatment group, which included pregnant women who were diagnosed with IDA in the 1st, 2nd or 3rd trimesters and who received antianemic therapy, and Group 2 (n = 30) – pregnant women with IDA (diagnosed in the 3rd trimester) who did not use any iron supplements.Results. In Group I, haemoglobin levels identified at the time of detection of anaemia ranged from 91 to 109 g/l (103.1 ± 4.5), red blood cell counts from 2.7 to 4.1 × 109/l (3.5 ± 0.3), and hematocrit levels from 26 to 37 (32.9 ± 1.8). Once the diagnosis of anaemia had been established, pregnant women were prescribed with Tardiferon 80 mg twice a day, which they administered on a regular basis until delivery and continued using during the postpartum period. In Group 2, patients did not receive any iron supplements and showed a gradual decrease in haemoglobin levels by an average of 5.6 g/l. Pregnant women receiving Tardyferon prolonged-release tablets from the date when anaemia was diagnosed showed an increase in clinical blood test values.Conclusions. In pregnant women with anaemia, iron therapy normalizes haematological parameters, which leads to improved tissue oxygen supply and a favourable clinical effect.
- 26 April 2025
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 4,p. 44-51
Open AccessThe course of pregnancy and childbirth in women with iron deficiency anemia treated with iron (II) sulfate and not treated
Introduction. Due to the plasma volume expansion prevailing over the increase in red blood cell production, as well as inadequate dietary intake with underlying physiologically increased iron requirements, pregnant women tend to suffer from iron deficiency and anaemia.Aim. To evaluate the efficacy of Tardyferon (depot iron (II) sulphate 80 mg) in pregnant women with anaemia in reducing adverse perinatal outcomes. Materials and methods. To conduct the retrospective chart review of pregnant women of Stavropol Krai, the patients were divided into 2 groups: Group 1 (n = 70) – the treatment group, which included pregnant women who were diagnosed with IDA in the 1st, 2nd or 3rd trimesters and who received antianemic therapy, and Group 2 (n = 30) – pregnant women with IDA (diagnosed in the 3rd trimester) who did not use any iron supplements.Results. In Group I, haemoglobin levels identified at the time of detection of anaemia ranged from 91 to 109 g/l (103.1 ± 4.5), red blood cell counts from 2.7 to 4.1 × 109/l (3.5 ± 0.3), and hematocrit levels from 26 to 37 (32.9 ± 1.8). Once the diagnosis of anaemia had been established, pregnant women were prescribed with Tardiferon 80 mg twice a day, which they administered on a regular basis until delivery and continued using during the postpartum period. In Group 2, patients did not receive any iron supplements and showed a gradual decrease in haemoglobin levels by an average of 5.6 g/l. Pregnant women receiving Tardyferon prolonged-release tablets from the date when anaemia was diagnosed showed an increase in clinical blood test values.Conclusions. In pregnant women with anaemia, iron therapy normalizes haematological parameters, which leads to improved tissue oxygen supply and a favourable clinical effect.
- Open Access
- 1 January 2025
- Published by Geotar-Media Publishing Group in Obstetrics and gynecology: News, Opinions, Training
- Vol. 13 (3)
Clinical features of various phenotypes of severe preeclampsia
Клинические особенности различных фенотипов тяжелой преэклампсии
- 1 January 2025
- Published by Geotar-Media Publishing Group in Obstetrics and gynecology: News, Opinions, Training
- Vol. 13 (3)
Open AccessClinical features of various phenotypes of severe preeclampsia
Клинические особенности различных фенотипов тяжелой преэклампсии
- Open Access
- 1 January 2025
- Published by Geotar-Media Publishing Group in Obstetrics and gynecology: News, Opinions, Training
- Vol. 13 (s)
Rational start of menopausal hormonal therapy: time, place, possibilities. Review of evidence
Рациональный старт менопаузальной гормональной терапии: время, место, возможности. Обзор доказательных данных
- 1 January 2025
- Published by Geotar-Media Publishing Group in Obstetrics and gynecology: News, Opinions, Training
- Vol. 13 (s)
Open AccessRational start of menopausal hormonal therapy: time, place, possibilities. Review of evidence
Рациональный старт менопаузальной гормональной терапии: время, место, возможности. Обзор доказательных данных
- Open Access
- 5 March 2024
- Published by Oxford University Press (OUP) in JAC-Antimicrobial Resistance
- Vol. 6 (2) , dlae041
The antibiotic knowledge, attitudes and behaviours of patients purchasing antibiotics with prescription in Russia: a qualitative, comparative analysis
Objectives: The study aimed to investigate behaviour, knowledge and practices towards antibiotic (AB) use among patients who purchased ABs with a prescription across Russia. Methods: Semi-structured interviews conducted in all eight Federal Districts, Moscow and Saint Petersburg in 2022 by 21 researchers trained specifically for this study. Data were analysed using a directed content analysis approach. Results: In total, 151 respondents were interviewed. Respiratory symptoms were the most common reason for AB prescription. The majority of patients discussed their complaints with family members or friends before consulting the physician and occasionally looked for information on antimicrobial treatment on the internet. The decision to use an AB was usually made by the physician, although patients often anticipated its prescription. Respondents typically chose to go to the nearest drug store to pick up the medicines, not seeking any recommendation from the local pharmacists. The level of knowledge about the effects of ABs was generally low. In most cases, patients were not aware of antimicrobial resistance and rarely recalled any information campaigns targeting prudent AB use. Respondents admitted COVID-19 had an impact on their behaviour: they have become more caring towards their health, but less likely to seek medical care because of the risk of infection. Conclusions: Our findings, in particular low awareness of the population about the effects of ABs and antimicrobial resistance, peculiarities of attitudes and behaviour (significant influence of the environment, tendency to self-diagnose, fairly high level of trust in doctors etc.) can be useful for the development of effective initiatives aiming for prudent AB use.
- 5 March 2024
- Published by Oxford University Press (OUP) in JAC-Antimicrobial Resistance
- Vol. 6 (2) , dlae041
Open AccessThe antibiotic knowledge, attitudes and behaviours of patients purchasing antibiotics with prescription in Russia: a qualitative, comparative analysis
Objectives: The study aimed to investigate behaviour, knowledge and practices towards antibiotic (AB) use among patients who purchased ABs with a prescription across Russia. Methods: Semi-structured interviews conducted in all eight Federal Districts, Moscow and Saint Petersburg in 2022 by 21 researchers trained specifically for this study. Data were analysed using a directed content analysis approach. Results: In total, 151 respondents were interviewed. Respiratory symptoms were the most common reason for AB prescription. The majority of patients discussed their complaints with family members or friends before consulting the physician and occasionally looked for information on antimicrobial treatment on the internet. The decision to use an AB was usually made by the physician, although patients often anticipated its prescription. Respondents typically chose to go to the nearest drug store to pick up the medicines, not seeking any recommendation from the local pharmacists. The level of knowledge about the effects of ABs was generally low. In most cases, patients were not aware of antimicrobial resistance and rarely recalled any information campaigns targeting prudent AB use. Respondents admitted COVID-19 had an impact on their behaviour: they have become more caring towards their health, but less likely to seek medical care because of the risk of infection. Conclusions: Our findings, in particular low awareness of the population about the effects of ABs and antimicrobial resistance, peculiarities of attitudes and behaviour (significant influence of the environment, tendency to self-diagnose, fairly high level of trust in doctors etc.) can be useful for the development of effective initiatives aiming for prudent AB use.
- Open Access
- 1 January 2024
- Published by Geotar-Media Publishing Group in Obstetrics and gynecology: News, Opinions, Training
- Vol. 12 (s)
Severe preeclampsia. Prediction of induced preterm birth
Тяжелая преэклампсия. Прогнозирование индуцированных преждевременных родов
- 1 January 2024
- Published by Geotar-Media Publishing Group in Obstetrics and gynecology: News, Opinions, Training
- Vol. 12 (s)
Open AccessSevere preeclampsia. Prediction of induced preterm birth
Тяжелая преэклампсия. Прогнозирование индуцированных преждевременных родов